Mylan Institutional Inc 2898 Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Mylan Institutional Inc 2898 Pharmaceutical Import Records from India — 11 Products, $26.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan Institutional Inc 2898 — Pharmaceutical Importer Profile (2026) | 11 Products, $26.8M Trade | TransData Nexus

Mylan Institutional Inc 2898

Pharmaceutical Importer · United States · Antibiotics Focus · $26.8M Total Trade · DGFT Verified

Mylan Institutional Inc 2898 is a pharmaceutical importer based in United States with a total trade value of $26.8M across 11 products in 8 therapeutic categories. Based on 636 verified import shipments from Indian Customs (DGFT) records, Mylan Institutional Inc 2898 is the #1 buyer in 3 products including Vancomycin, Famotidine, Docetaxel. Mylan Institutional Inc 2898 sources from 2 verified Indian suppliers, with Mylan Laboratories Limited accounting for 99.2% of imports.

Mylan Institutional Inc 2898 — Import Portfolio & Supplier Network

Mylan Institutional Inc 2898 import network — 11 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mylan Institutional Inc 2898?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$61.7M	1,369	99.2%
Steriscience Specialties Private Limited	$493.2K	11	0.8%

Mylan Institutional Inc 2898 sources from 2 verified Indian suppliers across .

What Formulations Does Mylan Institutional Inc 2898 Import?

Formulation	Value	Ships
Famotidine INJ USP 10MG/ML 2ML 25s	$2.1M	58
Dexametha sod INJ USP 4MG/ML 1ML 25	$2.1M	42
Acetaminophe INJ 1000MG/100ML 24s myl	$1.3M	47
Vanco hcl foi USP 1.25g 10s mylan us	$1.3M	25
Haloperidol INJ USP 5MG/ML 25s mylan	$729.2K	16
Dexametha sod INJ USP 4MG/ML 5ML 25	$651.7K	15
Dexametha sod INJ USP 4MG/ML 1ML	$600.0K	12
Vancomycin hcl foi USP 1g 10s mylan us	$550.0K	11
Norepinephr bitar INJ 1MG 4ML 10s myl	$500.0K	10
Fosaprepitant foi 150MG 10ML 1s mylan	$400.0K	8
Docetaxel INJ USP 10MG/ML 16ML 1s myl	$400.0K	8
Adenosine INJ USP 3MG/ML 2ML 10s myl	$400.0K	8
Eptifibatide INJ 2MG 10ML 1s myl us	$350.0K	7
Moxifloxacin hcl INJ 1.6MG/ML 12s us	$335.7K	7
Famotidine INJ USP 10MG/ML 25s mylan	$300.8K	8

Mylan Institutional Inc 2898 imports 947 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 11 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Vancomycin	Antibiotics	$5.8M	116	6.3%	1
2	Famotidine	Gastrointestinal	$5.0M	138	8.9%	1
3	Amino	Nutritional Supplements	$4.2M	143	1.3%	11
4	Docetaxel	Oncology	$3.3M	65	8.2%	1
5	Heparin	Cardiovascular	$2.9M	57	0.8%	7
6	Dexamethasone	Corticosteroids	$1.9M	39	1.1%	13
7	Gemcitabine	Oncology	$1.1M	21	2.3%	3
8	Doxycycline	Antibiotics	$1.0M	20	0.8%	6
9	Tobramycin	Antibiotics	$850.0K	17	2.2%	9
10	Moxifloxacin	Advanced Antibiotics	$742.1K	16	2.3%	3
11	Oxaliplatin	Advanced Oncology	$200.0K	4	0.4%	17

Mylan Institutional Inc 2898 imports 11 pharmaceutical products across 8 categories into United States totaling $26.8M. The company is the #1 buyer for 3 products: Vancomycin, Famotidine, Docetaxel.

Mylan Institutional Inc 2898 — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylan Institutional Inc. is a prominent pharmaceutical importer and buyer based in the United States, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company operates as a subsidiary of Viatris Inc., a global healthcare company formed in November 2020 through the merger of Mylan N.V. and Upjohn, Pfizer's off-patent medicine division. Viatris is headquartered in Canonsburg, Pennsylvania, and offers a diverse portfolio of generic and specialty pharmaceuticals across various therapeutic areas.

Mylan Institutional Inc. plays a critical role in the United States pharmaceutical distribution network by sourcing and importing a wide range of finished pharmaceutical products. These products are subsequently distributed to various stakeholders within the healthcare system, including hospitals, clinics, and pharmacies. The company's strategic focus on importing finished formulations enables it to meet the diverse needs of the U.S. market, ensuring a steady supply of essential medications across multiple therapeutic categories.

2Distribution Network

Mylan Institutional Inc. maintains a robust distribution network within the United States, with its primary facility located at 2898 Manufacturers Road, Greensboro, NC 27406-4600. This central location facilitates efficient logistics and distribution operations, ensuring timely delivery of pharmaceutical products to various regions across the country. The company's logistics capabilities are supported by advanced supply chain management systems, enabling effective coordination with international suppliers and domestic distributors. While specific details regarding additional warehouse locations and geographic coverage beyond the United States are not publicly disclosed, Mylan Institutional Inc.'s affiliation with Viatris Inc. suggests a global distribution reach, leveraging Viatris's extensive international presence to source and distribute pharmaceutical products worldwide.

3Industry Role

In the United States pharmaceutical supply chain, Mylan Institutional Inc. functions primarily as a pharmaceutical importer and buyer, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company's strategic focus on importing finished products allows it to meet the diverse needs of the U.S. market, ensuring a steady supply of essential medications across multiple therapeutic categories. By sourcing a wide range of pharmaceutical products, Mylan Institutional Inc. contributes to the overall efficiency and resilience of the U.S. healthcare system, facilitating access to a broad spectrum of medications for healthcare providers and patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mylan Institutional Inc 2898

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mylan Institutional Inc. demonstrates a high degree of sourcing concentration, with a significant majority of its pharmaceutical imports originating from a single supplier, Mylan Laboratories Limited. This supplier accounts for approximately 99.2% of the company's total import value, indicating a strong dependency on this supplier for the majority of its product offerings. Such a concentrated sourcing strategy can present both advantages and risks. On the one hand, it may lead to favorable terms and streamlined logistics due to the volume of business conducted with a single supplier. On the other hand, this dependency exposes Mylan Institutional Inc. to potential supply chain disruptions if issues arise with Mylan Laboratories Limited, such as production delays, quality concerns, or regulatory challenges. The company's reliance on a single supplier underscores the importance of maintaining a robust and resilient supply chain, with contingency plans in place to mitigate potential risks associated with supplier concentration.

2Supply Chain Resilience

Mylan Institutional Inc.'s supply chain resilience is closely tied to the stability and reliability of its primary supplier, Mylan Laboratories Limited. Given the high volume of imports from this supplier, any disruptions in Mylan Laboratories Limited's operations could significantly impact Mylan Institutional Inc.'s ability to meet the demands of the U.S. market. To enhance supply chain resilience, it is advisable for Mylan Institutional Inc. to diversify its supplier base, incorporating additional suppliers to reduce dependency on a single source. This diversification strategy would mitigate risks associated with potential disruptions and ensure a more stable and continuous supply of pharmaceutical products. Additionally, establishing strong relationships with multiple suppliers and maintaining open lines of communication can further strengthen the supply chain, enabling Mylan Institutional Inc. to respond more effectively to unforeseen challenges.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the approval and regulation of pharmaceutical products. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs, ensuring their safety and efficacy, and monitoring the quality of drugs on the market. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which provides the legal framework for the FDA's regulatory activities, and the Drug Enforcement Administration (DEA) regulations, which control the importation of controlled substances. For Indian pharmaceutical exporters, obtaining FDA approval for their products is essential to enter the U.S. market. This process involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) to the FDA, demonstrating that the product meets the agency's standards for safety, efficacy, and quality.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. Indian pharmaceutical exporters must ensure that their products comply with the FDA's Good Manufacturing Practice (GMP) standards, which are aligned with international guidelines such as the World Health Organization (WHO) GMP and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These standards encompass various aspects of manufacturing, including quality control, facility conditions, and personnel qualifications. Additionally, Indian exporters must obtain an FDA Establishment Identifier (FEI) number and register their manufacturing facilities with the FDA. Wholesale distribution authorization is also required, which involves obtaining a state-specific license to distribute pharmaceutical products within the United States. Compliance with these regulatory requirements is crucial for Indian exporters to establish and maintain a successful partnership with U.S. importers like Mylan Institutional Inc.

Mylan Institutional Inc 2898 — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mylan Institutional Inc.'s product category focus on antibiotics, gastrointestinal medications, and oncology drugs aligns with the significant demand for these therapeutic areas in the United States. The high import values and volume of shipments in these categories indicate a strategic emphasis on meeting the substantial market needs for these medications. The company's position as the leading buyer in vancomycin, famotidine, and docetaxel underscores its commitment to providing essential treatments in these critical areas. This product strategy enables Mylan Institutional Inc. to address prevalent health conditions and contribute to the overall healthcare infrastructure by ensuring a reliable supply of these vital medications.

2Sourcing Profile

Mylan Institutional Inc.'s sourcing strategy is characterized by a strong reliance on Indian suppliers, particularly Mylan Laboratories Limited, for a substantial portion of its pharmaceutical imports. This focus on Indian suppliers is strategic, given India's robust pharmaceutical manufacturing capabilities and adherence to international quality standards. The company's preference for finished pharmaceutical formulations aligns with the need to provide ready-to-use products to the U.S. market, ensuring efficiency and compliance with regulatory requirements. By leveraging India's manufacturing strengths, Mylan Institutional Inc. can offer a diverse and high-quality product portfolio to meet the demands of the U.S. healthcare system.

Frequently Asked Questions — Mylan Institutional Inc 2898

What products does Mylan Institutional Inc 2898 import from India?

Mylan Institutional Inc 2898 imports 11 pharmaceutical products across 8 categories. Top imports: Vancomycin ($5.8M), Famotidine ($5.0M), Amino ($4.2M), Docetaxel ($3.3M), Heparin ($2.9M).

Who supplies pharmaceuticals to Mylan Institutional Inc 2898 from India?

Mylan Institutional Inc 2898 sources from 2 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (99.2% of imports, $61.7M).

What is Mylan Institutional Inc 2898's total pharmaceutical import value?

Mylan Institutional Inc 2898's total pharmaceutical import value from India is $26.8M, based on 636 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mylan Institutional Inc 2898 focus on?

Mylan Institutional Inc 2898 imports across 8 categories. The largest: Antibiotics (28.5%), Gastrointestinal (18.5%), Oncology (16.0%).

Get Full Mylan Institutional Inc 2898 Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Mylan Institutional Inc 2898

Mylan Institutional Inc 2898 — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Mylan Institutional Inc 2898?

What Formulations Does Mylan Institutional Inc 2898 Import?

What Products Does Mylan Institutional Inc 2898 Import?

Top Products by Import Value

Mylan Institutional Inc 2898 Therapeutic Categories — 8 Specializations